Eales disease (ED) is a common, idiopathic, inflammatory retinal vasculitis that particularly affects young adults. Current treatments available for ED include corticosteroids, laser photocoagulation, retinal cryotherapy, and surgery, but a recent study found that using intravitreal bevacizumab injections may produce better outcomes and reduce the need for surgery.
Eales disease (ED) is a common, idiopathic, inflammatory retinal vasculitis that particularly affects young adults. The pathogenesis of ED is poorly understood, but some studies have attributed the disease to a response to Mycobacterium Tuberculosis antigens. The disease involves stages of retinal vasculitis, nonperfusion, neovascularization, vitreous hemorrhage (VH) and tractional retinal detachment (TRD).
Current treatments available for ED include corticosteroids, laser photocoagulation, retinal cryotherapy, and surgery, but a recent study, published in the Pakistan Journal of Medical Sciences, found that using intravitreal bevacizumab injections to treat ED may produce better outcomes and reduce the need for surgery.
The paper reports on a trial carried out at a single center from May 2015 to December 2016 in 26 patients—and 52 eyes—diagnosed with ED. Patients were randomized to receive either intravitreal bevacizumab injections or standard treatment with steroids and photocoagulation.
In the group that received bevacizumab, 9 eyes (24.6%) progressed to stage III or stage IV disease, while in the standard treatment group, 18 eyes (69.2%) progressed in disease severity. Six eyes in the bevacizumab group and 16 in the standard treatment group required surgery.
The groups showed comparable regression of vasculitis, but regression of neovascularization was observed more in the bevacizumab group (16 eyes) than the standard treatment group (6 eyes).
The difference in both groups in terms of final disease stage at 12 weeks was not statically significant (P = .066), though the number of eyes in stage I was 15 (58%) in the bevacizumab group versus 6 (23%) in the standard treatment group. “This shows considerably more number of eyes showing regression of ED,” write the authors.
The authors conclude that giving intravitreal bevacizumab injections monthly in patients with stage I or stage II ED results in more regression in vascularization and less need for surgery versus standard therapy, and it should be considered as an adjunct therapy to avoid progression of the disease.
Reference
Mehboob MA, Tahir M, Batool H. Role of intravitreal bevacizumab in management of Eale’s disease. Pak J Med Sci. 2018;34(2):333-337. doi: 10.12669/pjms.342.14483.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.